Beyond natriuretic peptides for diagnosis and management of heart failure

Clinical Chemistry

Volumn 63, Issue 1, 2017, Pages 211-222

  Ibrahim, Nasrien E ^a   Januzzi, James L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ARGIPRESSIN; BIOLOGICAL MARKER; COPEPTIN; CYSTATIN C; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 23; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; MATRIX METALLOPROTEINASE; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE INHIBITOR; MYELOPEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; NATRIURETIC FACTOR; NEUROHORMONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOSTATIN RECEPTOR 2; TROPONIN; TUMOR NECROSIS FACTOR;

CARDIAC MUSCLE CELL; CARDIOVASCULAR INFLAMMATION; CELL DAMAGE; CELL DEATH; EXTRACELLULAR MATRIX; GENETIC MARKER; HEART FAILURE; HEART STRESS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY INJURY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR REMODELING; METABOLISM; PATHOPHYSIOLOGY;

BIOMARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES;

EID: 85008499539     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.259564     Document Type: Review

References (80)

1. Januzzi JL, Felker GM. Surfing the biomarker tsunami at JACC: heart failure. JACC Heart Fail 2013;1:213-5.
2. NIH. Precision medicine initiative https://www. Nih. Gov/precision-medicine-initiative-cohort-program (Accessed January 2016).
3. Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail 2014;2:477-88.
4. Januzzi JL, van Kimmenade RRJ. Importance of rigorous evaluation in comparative biomarker studies. J Am Coll Cardiol 2014;63:167-9.
5. van Kimmenade RRJ, Januzzi JL. Emerging biomarkers in heart failure. Clin Chem 2012;58:127-38.
6. Braunwald E. Heart failure. JACC Heart Fail 2013;1:1-20.
7. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
8. Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012;33:2197-205.
9. Vodovar N, Séronde M-F, Laribi S, Gayat E, Lassus J, Boukef R, et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014;35:3434-41.
10. Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther 2015:1-14.
11. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012;58:1673-81.
12. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015;443:57-70.
13. Januzzi JJL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-13.
14. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
15. Piper S, Hipperson D, deCourcey J, Sherwood R, George Amin-Youssef AS, McDonagh T. 50 biological variability of soluble ST2 in stable chronic heart failure. Heart 2014;100:A29.
16. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008;14:732-8.
17. Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin t measurements in patients with chronic heart failure. JACC Heart Fail 2014;2:65-72.
18. Maisel A, Xue Y, van Veldhuisen DJ, Voors AA, Jaarsma T, Pang PS, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol 2014;114:737-42.
19. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail 2013;6:1206-13.
20. Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the valsartan heart failure trial. Circ Heart Fail 2014;7:418-26.
21. Dieplinger B, Egger M, Gegenhuber A, Haltmayer M, Mueller T. Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta 2015;451, Part B: 310-5.
22. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-β superfamily protein. Circ Res 2006;98:294-7.
23. Cotter G, Voors AA, Prescott MF, Felker GM, Filippatos G, Greenberg BH, et al. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail 2015;17:1133-43.
24. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growthdifferentiation factor-15 in heart failure: Relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 2010;122:1387-95.
25. Chan MMY, Santhanakrishnan R, Chong JPC, Chen Z, Tai BC, Liew OW, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2016;18:81-8.
26. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-52.
27. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'Donnell TF, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensinconverting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014;63:2421-8.
28. Scialla JJ. Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. Curr Opin Nephrol Hypertens 2015;24:260-7.
29. López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J AmColl Cardiol 2016;67:251-60.
30. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-7.
31. Buralli S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E, et al. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 2010;105:853-6.
32. Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, Angermann CE. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008;10:388-95.
33. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-6.
34. Zile MR, DeSantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011;4:246-56.
35. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8.
36. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24.
37. Bayés-Genís A. Neprilysin in heart failure: from oblivion to center stage. JACC Heart Fail 2015;3:637-40.
38. Sanders-van Wijk S, Masson S, Milani V, Rickenbacher P, Gorini M, Tavazzi LT, et al. Interaction of galectin-3 concentrations with the treatment effects of β-blockers and RAS blockade in patients with systolic heart failure: a derivation-validation study from TIME-CHF and GISSIHF. Clin Chem 2016;62:605-16.
39. Pascual-Figal DA, Casas T, Ordonez-Llanos J, Manzano-Fernández S, Bonaque JC, Boronat M, et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J 2012;163:1002-10.
40. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011;57:2406-8.
41. Parissis JT, Papadakis J, Kadoglou NPE, Varounis C, Psarogiannakopoulos P, Rafouli-Stergiou P, et al. Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and nondetectable conventional troponin T levels. Int J Cardiol 2013;168:3609-12.
42. Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. J Cardiovasc Transl Res 2015;8:164-72.
43. Pang PS, Teerlink JR, Voors AA, Ponikowski P, Greenberg BH, Filippatos G, et al. Use of high-sensitivity troponin T to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX-AHF trial. JACC Heart Fail 2016;4:591-5.
44. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2014;131:54-61.
45. Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N, et al. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 2010;56:944-51.
46. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
47. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-91.
48. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-9.
49. Tang WH, Shrestha K, Martin MG, Borowski AG, Jasper S, Yandle TG, et al. Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure. J Card Fail 2010;16:635-40.
50. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers In Acute Heart Failure (BACH) study. Circ Heart Fail 2011;4:613-20.
51. Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, et al. Complementary role of copeptin and highsensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 2011;13:726-33.
52. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 2011;305:2088-95.
53. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118:410-21.
54. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al. Mid-regional proadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484-91.
55. Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013;1832:2442-50.
56. Manzano-Fernández S, Flores-Blanco PJ, Pérez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sánchez FJ, Morales-Rull JL, et al. Comparison of risk prediction with the CKD-EPI and MDRD equations in acute decompensated heart failure. J Card Fail 2013;19:583-91.
57. Flores-Blanco PJ, Manzano-Fernández S, Pérez-Calvo JI, Pastor-Pérez FJ, Ruiz-Ruiz FJ, Carrasco-Sánchez FJ, et al. Cystatin c-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure. Clin Cardiol 2015;38:106-13.
58. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin c. N Engl J Med 2012;367:20-9.
59. Curhan G. Cystatin C: a marker of renal function or something more? Clin Chem 2005;51:293-4.
60. Dupont M, Wu Y, Hazen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail 2012;5:602-9.
61. Manzano-Fernández S, Januzzi JL Jr, Boronat-Garcia M, Bonaque-González JC, Truong QA, Pastor-Pérez FJ, et al. β-trace protein and cystatin C as predictors of longterm outcomes in patients with acute heart failure. J Am Coll Cardiol 2011;57:849-58.
62. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-Type NaTriuretic Peptide In Acutely Decompensated Heart Failure (GALLANT) trial. Eur J Heart Fail 2011;13:846-51.
63. De Berardinis B, Gaggin Hanna K, Magrini L, Belcher A, Zancla B, Femia A, et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clin Chem Lab Med 2015;53:613-21.
64. Legrand M, De Berardinis B, Gaggin HK, Magrini L, Belcher A, Zancla B, et al. Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study. PLoS One 2014;9:e112313.
65. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010;96:1297-302.
66. Grodin JL, Perez AL, Wu Y, Hernandez AF, Butler J, Metra M, et al. Circulating kidney injury molecule-1 levels in acute heart failure: Insights from the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). JACC Heart Fail 2015;3:777-85.
67. Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail 2013;1:417-24.
68. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 2011;57:2233-41.
69. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
70. Januzzi JL. B-type natriuretic peptide testing in the era of neprilysin inhibition: are the winds of change blowing? Clin Chem 2016;62:663-5.
71. Bayés-Genís A, Barallat J, Pascual-Figal D, Nuñez J, Miñana G, Sánchez-Mas J, et al. Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study. JACC Heart Fail 2015;3:641-4.
72. Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail 2016;18:89-93.
73. Levy WC, Anand IS. Heart failure risk prediction models: what have we learned? JACC Heart Fail 2014;2:437-9.
74. 2015 AHA late-breaking basic science abstracts. Circ Res 2015;117:e121-e7.
75. Maciejak A, Kiliszek M, Michalak M, Tulacz D, Opolski G, Matlak K, et al. Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Med 2015;7:1-15.
76. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-7.
77. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012;5:183-90.
78. Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 2013;168:1251-7.
79. Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, et al. Development of a novel heart failure risk tool: the Barcelona Bio-Heart Failure Risk calculator (BCN BIO-HF calculator). PLoS One 2014;9:e85466.
80. Berezin AE, Kremzer AA, Martovitskaya YV, Berezina TA, Samura TA. The utility of biomarker risk prediction score in patients with chronic heart failure. Clin Hypertens 2016;22:1-11.